OCUGEN CEO Sells Nearly 12% of Shares in Rule 10b5‑1 Plan Amid Sharp Market Decline and Rising Insider Buying Confidence
OCUGEN CEO’s 10b5‑1 sale of nearly 470k shares at $1.12 shows disciplined liquidity strategy amid a 27% YTD drop, yet reflects confidence in long‑term growth.
2 minutes to read